Press Release: Vytronus : Vytronus Reaches Enrollment Milestone in Clinical Trial of Automated Ultrasound Technology for Treatment of Persistent Atrial Fibrillation

Vytronus, Inc., a privately held medical device company developing novel technologies for the treatment of cardiac arrhythmias, announced today that its early feasibility study of automated ultrasound technology for the treatment of persistent atrial fibrillation recently passed the midpoint in patient enrollment and is on track for completion of enrollment in mid-2019.